Research and Development Department, Cadila Pharmaceuticals Limited, India
*Corresponding Author: Bakulesh Khamar, Research and Development Department, Cadila Pharmaceuticals Limited, India.
Received: January 29, 2018; Published: February 12, 2018
Citation: Bakulesh Khamar. “EGFR Mutant Non-Small Cell Lung Cancer: Current Status and Future Perspective”. Acta Scientific Cancer Biology 2.2 (2018).
Epidermal growth factor receptor (EGFR ) mutant Non-small cell lung cancer (NSCLC) carries better prognosis compared to other varieties of NSCLC even when treated by chemotherapy. The usage of EGFR inhibitors (EGFRI) is associated with better response rate (up to 87.8%) and improved Progression free survival (PFS) compared to chemotherapy. The outcome of therapy depends on type of EGFR mutant present as well as the prescribed EGFRI. In general improvement in Overall survival (OS) is not seen with use of EGFRI. Commonly expressed EGFR mutants include del790 and L858. They are sensitive to reversible EGFRI gefitinib and erlotinib. Progression of disease on EGFRI is associated with several factors. De-novo presence of mutant T790M is seen in 50% of tumors at progression. Osimertinib is a third generation irreversible EGFRI which acts on commonly expressed EGFR mutant as well as T790M. It provides better outcome as a second line therapy. Recently, it is found to be better than reversible EGFRI in first line therapy also. There are also some efforts to improve outcome by focusing on better EGFRI and/or combining EGFRI with other therapies like chemotherapy, vascular endothelial growth factor (VEGF) inhibitors and immunotherapy. This mini review provides overview of current status and potential future therapies.
Keywords: EGFR Mutant NSCLC; EGFR Inhibitors; Immunotherapy
Copyright: © 2018 Bakulesh Khamar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.